Cargando…

Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells

BACKGROUND: Curative treatments for patients with metastatic synovial sarcoma (SS) do not exist, and such patients have a poor prognosis. We explored combinations of molecularly-targeted and cytotoxic agents to identify synergistic treatment combinations in SS cells. METHODS: Two SS cell lines (HS-S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgan, Sherif S, Cranmer, Lee D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247709/ https://www.ncbi.nlm.nih.gov/pubmed/25406429 http://dx.doi.org/10.1186/1756-0500-7-812

Ejemplares similares

Ridaforolimus
Publicado: (2012)

Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus
por: Keedy, Vicki L
Publicado: (2012)

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
por: Becker, Marc A., et al.
Publicado: (2016)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Pharmacokinetic Evaluation of a DSPE-PEG(2000) Micellar Formulation of Ridaforolimus in Rat
por: Remsberg, Connie M., et al.
Publicado: (2012)

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
por: Pearson, Andrew D.J., et al.
Publicado: (2016)

A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
por: Liu, Lian, et al.
Publicado: (2013)

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
por: Chon, Hye Sook, et al.
Publicado: (2017)

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer
por: Lush, Richard M., et al.
Publicado: (2012)

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
por: Seki, Yoshitaka, et al.
Publicado: (2011)

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
por: Colombo, N, et al.
Publicado: (2013)

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
por: Brana, I, et al.
Publicado: (2014)

The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
por: Chao, Min-Wu, et al.
Publicado: (2015)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma
por: Laporte, Aimée N., et al.
Publicado: (2017)

Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways
por: Sampson, Valerie B., et al.
Publicado: (2015)

Synergism of Heat Shock Protein 90 and Histone Deacetylase Inhibitors in Synovial Sarcoma
por: Nguyen, Anne, et al.
Publicado: (2009)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
por: Hrzenjak, Andelko, et al.
Publicado: (2010)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Primary retroperitoneal synovial sarcoma in CT and MRI
por: Alhazzani, Abdulmajeed R., et al.
Publicado: (2010)

Synovial-cell sarcoma
por: Nugud, Ahmed, et al.
Publicado: (2019)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

GI Synovial Sarcomas
por: Sinniah, Rajeev Palar, et al.
Publicado: (2012)

Synovial sarcoma of the mandible
por: Khalili, Maryam, et al.
Publicado: (2012)

Pulmonary synovial sarcoma
por: Gupta, Ankit, et al.
Publicado: (2018)

Synovial Sarcoma of the Hand
por: Ohan, Hovsep, et al.
Publicado: (2020)

Differential Response of Mycosis Fungoides Cells to Vorinostat
por: Bordeaux, Zachary A., et al.
Publicado: (2023)

Primary Cutaneous Synovial Sarcoma: An Extremely Rare Report of Superficial Synovial Sarcoma
por: Namazi, Nastaran, et al.
Publicado: (2016)

Metastatic biomarkers in synovial sarcoma
por: de Necochea-Campion, Rosalia, et al.
Publicado: (2017)

Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
por: Okubo, Kazuki, et al.
Publicado: (2019)

Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines
por: Bernhart, Eva, et al.
Publicado: (2017)

Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
por: Bergadà, Laura, et al.
Publicado: (2014)

Primary renal synovial sarcoma
por: Bakhshi, Girish D., et al.
Publicado: (2012)

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
por: Lee, Jin, et al.
Publicado: (2012)

Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas
por: Morgan, Sherif S, et al.
Publicado: (2014)

Vorinostat (SAHA) and Breast Cancer: An Overview
por: Wawruszak, Anna, et al.
Publicado: (2021)

Primary synovial sarcoma of lung
por: Devleena,, et al.
Publicado: (2014)

Primary Synovial Sarcoma of Lung
por: Cabuk, Devrim, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7m475tsqsj3q6s8bfirg6jc9ha